ArticlePharmaceutics2020
Chitosan Hydrogel Doped with PEG-PLA Nanoparticles for the Local Delivery of miRNA-146a to Treat Allergic Rhinitis.
Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Research progress and applications of functional hydrogels in nasal wound healing.Journal of biological engineering · 2026Review
- A pH-responsive miR-146a-loaded Gel/MSN nanocarrier enhances anti-inflammatory efficacy in allergic rhinitis through pyroptosis suppression.Journal of translational medicine · 2026Article
- [Applications of novel biomaterials in the research and treatment of allergic rhinitis].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2026Review
- Hydrogels-Advanced Polymer Platforms for Drug Delivery.Polymers · 2026Review
- Advances in Nanotechnology-Based Immunomodulatory Strategies for the Treatment of Allergic Rhinitis.International journal of nanomedicine · 2026Review
- Nanoparticle-Based Targeted Drug Delivery Systems for Allergic Rhinitis: A Comprehensive Review.International journal of nanomedicine · 2026Review
- Nanocomposite hydrogel incorporating Arnica montana extract, propolis-loaded chitosan nanoparticles, and menstrual blood-derived mesenchymal stem cells for allergic rhinitis therapy.Journal of materials science. Materials in medicine · 2025Article
- Potential MiRNA therapies for premature ovarian failure: new challenges and opportunities.Stem cell research & therapy · 2025Review
- Intranasal Application of Foxp3 Introduced with Poly(d,l-lactic-Pharmaceutics · 2025Article
- Hydrogels as Suitable miRNA Delivery Systems: A Review.Polymers · 2025Review
- Nanotechnology-Based Therapeutics for Airway Inflammatory Diseases.Clinical reviews in allergy & immunology · 2025Review
- Hydrogel Encapsulation Techniques and Its Clinical Applications in Drug Delivery and Regenerative Medicine: A Systematic Review.ACS omega · 2024Review
- Article
- Hydrogels for Mucosal Drug Delivery.ACS applied bio materials · 2023Review
- Mechanisms and application strategies of miRNA‑146a regulating inflammation and fibrosis at molecular and cellular levels (Review).International journal of molecular medicine · 2023Review
- Multiple Roles of Chitosan in Mucosal Drug Delivery: An Updated Review.Marine drugs · 2022Review
- MicroRNA-214-3p facilitates M2 macrophage polarization by targeting GSK3B.The Kaohsiung journal of medical sciences · 2022Article
- Emerging Fabrication Strategies of Hydrogels and Its Applications.Gels (Basel, Switzerland) · 2022Review
- Mechanisms of hydrogel-based microRNA delivery systems and its application strategies in targeting inflammatory diseases.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
To prepare a binary formulation delivering miRNA-146 and evaluate a nucleic acid nasal delivery system by investigating its pharmacodynamic effects in allergic rhinitis. The gel/NPs/miR-146a thermosensitive in situ chitosan hydrogel carrying a nucleic acid was prepared and evaluated for its characteristics, including temperature sensitivity, gel strength, mucosal adhesion and drug release profile. After nasal administration of the formulation to ovalbumin-sensitized rats, the treatment of allergic rhinitis was verified by assessing nasal symptoms, hematology, hematoxylin-eosin (HE) staining and immunohistochemistry. Western Blot(WB) was used to analyze nasal inflammatory factors as well as miRNA-146-related factors, and the miR146 expression level was measured by PCR. Subsequently, the effects of the gel/NPs/miR-146a binary formulation were evaluated for the nasal delivery of nucleic acids in rhinitis therapy. The prepared binary formulation quickly formed a gel in the nasal cavity at a temperature of 34 °C with good mucosal adhesion, which delivered nucleic acids into the nasal mucosa stably and continuously. Gel/NPs/miR-146a was able to sustain the delivery of miRNA into the mucosa after nasal administration. When compared with the monolithic formulations, the gel/NPs/miR-146a binary formulation performed better regarding its nucleic acid delivery ability and pharmacodynamic effects. The gel/NPs/miR-146a binary preparation has a suitable nasal mucosal drug delivery ability and has a positive pharmacodynamic effect for the treatment of ovalbumin-induced rhinitis in rats. It can serve as a potential nucleic acid delivery platform for the treatment of allergic rhinitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.